An investigational vaccine developed by Moderna is being tested for safety and immune response in Seattle and 3 other cities.
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
A registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
Dr. Jennifer Nelson explains how Kaiser Permanente scientists are helping the CDC and FDA keep an eye out for rare adverse events.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
KPWHRI responded to the COVID-19 hurricane with actions to improve health worldwide.
In a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.